Cipla unveils generic hepatitis C drug 'Hepcvir-L'

21 Dec 2015 Evaluate

Cipla has unveiled generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India. Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patient. The company's product is a generic version of the S-based drug maker Gilead Sciences Inc's Harvoni tablets.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Cipla Share Price

1316.00 -12.25 (-0.92%)
29-Jan-2026 12:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1597.10
Dr. Reddys Lab 1203.25
Cipla 1316.00
Zydus Lifesciences 887.30
Lupin 2115.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×